Agios Pharmaceuticals Future Growth

Future criteria checks 2/6

Agios Pharmaceuticals is forecast to grow earnings and revenue by 31.3% and 48.8% per annum respectively. EPS is expected to grow by 34.6% per annum. Return on equity is forecast to be -39.2% in 3 years.

Key information

31.3%

Earnings growth rate

34.6%

EPS growth rate

Biotechs earnings growth	25.1%
Revenue growth rate	48.8%
Future return on equity	-39.2%
Analyst coverage	Good
Last updated	18 May 2024

Recent future growth updates

Recent updates

Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates

Feb 17

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Jan 16

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%

Nov 09

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Sep 26

Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

May 08

We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely

Feb 06

Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans

Oct 18

Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU

Sep 16

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 46%

Dec 21

Agios Pharmaceuticals: A Near-Term Capital Gain Prospect Seen By Market-Makers As Underpriced

Sep 07

Agios submits mitapivat application in U.S. for pyruvate kinase deficiency

Jun 21

Earnings and Revenue Growth Forecasts

NasdaqGS:AGIO - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	201	-286	-224	N/A	8
12/31/2025	114	-345	-237	-277	9
12/31/2024	43	-263	-320	-98	7
3/31/2024	29	-353	-319	-301	N/A
12/31/2023	27	-352	-315	-296	N/A
9/30/2023	24	-220	-308	-290	N/A
6/30/2023	20	-210	-300	-299	N/A
3/31/2023	19	-218	-309	-307	N/A
12/31/2022	14	-232	-314	-309	N/A
9/30/2022	10	-367	-337	-327	N/A
6/30/2022	6	-369	-350	-341	N/A
3/31/2022	1	-360	-392	-384	N/A
12/31/2021	N/A	-357	-413	-407	N/A
9/30/2021	N/A	-342	-374	-373	N/A
6/30/2021	N/A	-337	-363	-356	N/A
3/31/2021	N/A	-336	-317	-306	N/A
12/31/2020	N/A	-329	-305	-291	N/A
9/30/2020	35	-347	-355	-335	N/A
6/30/2020	61	-374	-370	-352	N/A
3/31/2020	88	-402	-387	-373	N/A
12/31/2019	N/A	-301	-383	-371	N/A
9/30/2019	112	-401	-358	-351	N/A
6/30/2019	102	-389	-337	-329	N/A
3/31/2019	116	-348	-316	-309	N/A
12/31/2018	94	-346	-311	-304	N/A
9/30/2018	74	-343	-312	-305	N/A
6/30/2018	70	-325	-325	-319	N/A
3/31/2018	41	-339	-316	-310	N/A
12/31/2017	43	-315	N/A	-285	N/A
9/30/2017	56	-283	N/A	-262	N/A
6/30/2017	53	-269	N/A	-233	N/A
3/31/2017	49	-241	N/A	-17	N/A
12/31/2016	70	-198	N/A	39	N/A
9/30/2016	53	-183	N/A	59	N/A
6/30/2016	50	-160	N/A	83	N/A
3/31/2016	56	-136	N/A	-70	N/A
12/31/2015	59	-118	N/A	-77	N/A
9/30/2015	68	-104	N/A	-54	N/A
6/30/2015	96	-60	N/A	-53	N/A
3/31/2015	91	-46	N/A	-58	N/A
12/31/2014	65	-54	N/A	-59	N/A
9/30/2014	57	-39	N/A	-65	N/A
6/30/2014	30	-55	N/A	-57	N/A
3/31/2014	28	-47	N/A	-71	N/A
12/31/2013	26	-44	N/A	-56	N/A
9/30/2013	25	-49	N/A	-54	N/A
6/30/2013	25	-40	N/A	-51	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AGIO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AGIO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AGIO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AGIO's revenue (48.8% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: AGIO's revenue (48.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: AGIO is forecast to be unprofitable in 3 years.

Agios Pharmaceuticals Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus revenue estimates decrease by 33%, EPS upgraded

Consensus revenue estimates increase by 46%

Consensus revenue estimates fall by 43%

Price target decreased to US$36.20

Price target increased to US$39.20

Consensus forecasts updated

Recent updates

Consensus revenue estimates decrease by 33%, EPS upgraded

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Shareholder dilution

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Chair of the Board of Directors exercised options and sold US$215k worth of stock

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 46%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates

Consensus revenue estimates fall by 43%

Agios Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Chair of the Board of Directors exercised options and sold US$232k worth of stock

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

CEO & Director exercised options and sold US$277k worth of stock

Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Agios Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Agios Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

CEO & Director exercised options and sold US$325k worth of stock

Agios Pharmaceuticals, Inc. Announces Board Changes

Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

Director exercised options and sold US$226k worth of stock

Director exercised options and sold US$262k worth of stock

Director exercised options and sold US$269k worth of stock

Director exercised options and sold US$326k worth of stock

Chair of the Board of Directors exercised options and sold US$105k worth of stock

We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely

Director exercised options and sold US$406k worth of stock

Director notifies of intention to sell stock

Insider exercised options and sold US$79k worth of stock

Agios Pharmaceuticals, Inc. Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Appoints Tsveta Milanova as Chief Commercial Officer, Effective Jan. 3, 2023

Price target decreased to US$36.20

Price target increased to US$39.20

Agios Pharmaceutical's PYRUKYND® Approves in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

Consensus forecasts updated

Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans

Agios Pharmaceuticals, Inc. Appoints Cecilia Jones as Chief Financial Officer, Effective September 26, 2022

Agios Pharmaceuticals, Inc. Receives Positive Chmp Opinion for Pyrukynd® (Mitapivat) for the Treatment of Pyruvate Kinase (Pk) Deficiency in Adult Patients

Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU

Agios Pharmaceuticals, Inc. Announces Resignation of Jonathan Biller as Chief Financial Officer, Effective September 16, 2022

Agios adds more than 13% after Novo deal to acquire rival Forma

Agios Pharmaceuticals, Inc. Appoints Rahul Ballal and Cynthia Smith to Board of Directors

Agios Pharmaceuticals, Inc. Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent a- and ß-Thalassemia

Insufficient new directors

Agios Pharmaceuticals GAAP EPS of -$1.68 beats by $0.07

Agios Pharmaceuticals Is A Buy On Coming Revenue Ramp

Agios Pharmaceuticals, Inc. Announces Management Changes, Effective August 8, 2022

Agios Pharmaceuticals appoints new board chair, CEO

Agios Presents New Clinical Data Supporting the Benefits of Pyrukynd® Treatment in Adults with PK Deficiency At European Hematology Association Annual Congress

Agios Pharmaceuticals, Inc. Announces Resignation of Bruce Car as Chief Scientific Officer, effective as of August 1, 2022

Agios Pharmaceuticals, Inc. Announces Management Changes

Agios Pharmaceuticals, Inc. Announces Executive Changes

Consensus forecasts updated

Agios: Approved Product, Upcoming Catalysts

Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

Price target decreased to US$41.17

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces Resignation of Ian T. Clark from the Board

Agios Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 05, 2022

Price target decreased to US$44.83

Price target increased to US$60.57

CEO & Director exercised options and sold US$107k worth of stock

Agios Pharmaceuticals With FDA Approval Is A Buy